GILEAD
Creating Possible

Q226 Financial Results

August 4, 2026

Forward-Looking Statements

Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead's ability to achieve its full year 2026 financial guidance, including as a result of the uncertainty of the amount and timing of Veklury revenues, the impact from Medicare Part D pricing reform in the Inflation Reduction Act, the expiration of subsidies related to the Affordable Care Act, our most-favored-nation pricing agreement with the U.S. government, changes in U.S. regulatory or legislative policies, and changes in U.S. trade policies, including tariffs; Gilead's ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy; Gilead's ability to accelerate or sustain revenues for its virology, oncology, inflammation and other programs; Gilead's ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the arrangements with Arcellx, Immunomedics, Lakefront, Merck, Ouro Medicines, The World Health Organization, and Tubulis; the risk that Gilead's U.S. manufacturing and R&D investment may not achieve their intended benefits; patent protection and estimated loss of exclusivity for our products and product candidates; Gilead's ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Livdelzi, Trodelvy, anito-cel, KITE-753, and lenacapavir (such as ASCENT-03, ASCENT-04, ASSURE, IDEAL, ISLEND-1, and ISLEND-2), and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead's product candidates or the product candidates of Gilead's strategic partners; Gilead's ability to resolve the issues cited by the FDA in pending clinical holds to the satisfaction of the FDA and the risk that FDA may not remove such clinical holds, in whole or in part, in a timely manner or at all; Gilead's ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines; Gilead's ability to receive or maintain regulatory approvals in a timely manner or at all, and the risk that any such approvals, if granted, may be subject to significant limitations on use and may be subject to withdrawal or other adverse actions by the applicable regulatory authority, including those involving Hepcludex, Trodelvy, and once-weekly oral Yeztugo; Gilead's ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead's products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of Gilead's products over other therapies, including Hepcludex and Trodelvy; Gilead's ability to effectively manage the access strategy relating to lenacapavir for HIV PrEP, subject to necessary regulatory approvals; and other risks identified from time to time in Gilead's reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended June 30, 2026 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

Contents

GILEAD
Creating Possible

Q226 Key Takeaways

Daniel O'Day
Chairman & Chief Executive Officer

Gilead Q226 - Key Takeaways

1 Business Performance

- Total Q226 Base Business up 10% YoY; strongest Q2 growth since 2023, driven by HIV, Trodelvy and Livdelzi
- Total Q226 HIV up 12% YoY; PrEP >$1B, up 101% YoY
- Q226 Trodelvy up 26% YoY; Liver up 10% YoY, with Livdelzi up 115%
- FY26 Base Business expected to grow 6-7% YoY; HIV expected to grow 9-10% YoY

2 Clinical Updates

- Positive P3 ISL/LEN updates at AIDS 2026; potential first weekly oral treatment for VS PWH with launch 2027
- Expect to initiate P3 trial evaluating LEN + TAB + ZAB, potential twice-yearly treatment for VS PWH
- GS-8824 (TUB-040) P1 PROC encouraging safety and efficacy data at ASCO 2026
- Positive P3 IDEAL topline results for Livdelzi in 2L PBC patients with ALP 1-1.67x ULN

3 Commercial Launches

- Launch momentum continues with 2 launches in Q226, 2 launches expected in 2H26
- Trodelvy launched in 1L PD-L1+ and PD-L1- mTNBC in the U.S.
- Hepcludex launched for chronic HDV in the U.S.; first and only FDA-approved HDV treatment
- BIC/LEN launch in VS PWH expected in August; anito-cel launch in R/R MM expected in December

Note: YoY reflects Q226 vs. Q225 or FY26 vs. FY25. Base business refers to Total Product Sales excluding Veklury. U.S. PrEP refers to Yeztugo and Descovy for PrEP sales. ALP - alkaline phosphatase, BIC/LEN - bictegravir/lenacapavir, HDV - hepatitis delta virus, ISL/LEN - islatravir/lenacapavir, mTNBC - metastatic triple negative breast cancer, PBC - primary biliary cholangitis, PROC - platinum resistant ovarian cancer, QW - weekly, R/R MM - relapsed or refractory multiple myeloma, TAB - teropavimab, ULN - upper limit normal, VS PWH - virally suppressed people with HIV, ZAB - zinlirvimab

GILEAD
Creating Possible

Commercial Results & Market Dynamics

Johanna Mercier
Chief Commercial &
Corporate Affairs Officer

Strong Base Business Performance in Q226



$7.6B **Total Product Sales excluding Veklury**
+10% YoY, +12% QoQ

$7.6B **Total Product Sales**
+8% YoY, +10% QoQ

$5.7B **HIV Product Sales**
+12% YoY, +13% QoQ

$877M **Liver Product Sales**
+10% YoY, +14% QoQ

$873M **Oncology Product Sales**
+3% YoY, +8% QoQ

Note: YoY reflects Q226 vs. Q225 and QoQ reflects Q226 vs. Q126.

HIV: Poised for Strongest Growth Since 2019

Product Sales ($M)



$5.7B
Q226 Sales

+12%
Q226 Growth YoY

- YoY driven by higher average realized price and higher demand
- QoQ driven by inventory build and higher average realized price
- 2026 HIV growth expectations increased to 9-10% YoY, from +8% YoY previously

Note: YoY reflects Q226 vs. Q225 and QoQ reflects Q226 vs. Q126.

HIV Treatment: Leadership in Dynamic Market

BIKTARVY®
bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets

Q226 sales: $3.8B; +7% YoY, +12% QoQ

#1
Regimen for naïve & switches across most major markets

>52%
U.S. Treatment Market Share

- **YoY** driven by higher average realized price due to channel mix, in addition to inventory build and higher demand
- **QoQ** driven by second quarter seasonality, partially offset by lower demand due to market dynamics
- Continues to increase share YoY

BIC/LEN

Daily Oral

PDUFA August 27, 2026

5-6%
PWH on Complex Regimens

Up to 20%
PWH Switch HIV Therapies Annually

- Combines bictegravir, the most prescribed integrase inhibitor, with lenacapavir, our breakthrough capsid inhibitor
- Potential U.S. launch in virally suppressed people with HIV

Note: YoY reflects Q226 vs. Q225 and QoQ reflects Q226 vs. Q126. BIC/LEN is an investigational once daily oral combination of bictegravir and lenacapavir and is not approved for any indication. Biktarvy (bictegravir 50 mg, emtricitabine 200 mg, tenofovir alafenamide 25 mg) tablets. PWH – people with HIV.

Quarterly HIV PrEP Sales Exceed $1B for First Time

+101%
PrEP Sales YoY

~14%
U.S. PrEP Market Growth YoY

yeztugo® (lenacapavir) injection 463.5mg/1.5mL

Q226 sales: $232M; +40% QoQ

- Leader in switch across all PrEP options (oral and LAI)
- Now leading LAI in naïve segment

Descovy®

PrEP Q226 sales*: $801M; +60% YoY, +23% QoQ

- YoY driven by higher average realized price and higher demand
- QoQ driven by typical second quarter seasonality and higher demand

*Descovy for PrEP sales are based on internal estimates. Note: HIV Prevention business includes Descovy for PrEP and Yeztugo (Truvada for PrEP is not included). YoY reflects Q226 vs. Q225. QoQ reflects Q226 vs. Q126. Descovy (emtricitabine 200 mg, tenofovir alafenamide 25 mg) tablets. LAI – long-acting injectable. PrEP – pre-exposure prophylaxis.

Liver Disease: Livdelzi Leading in 2L PBC

Product Sales ($M)



Livdelzi® seladelpar 10mg Capsules

$167M
Q226 Livdelzi Sales

>50%
2L PBC U.S. Market Share

- Livdelzi launch momentum continues (+115% YoY, +26% QoQ) and remains leading 2L PBC regimen

- Total Liver +10% YoY driven by higher demand across PBC, HBV and HDV, offset by lower HCV starts
- Total Liver +14% QoQ driven by higher demand and inventory build, partially offset by lower average realized price

Note: HCV includes Epclusa, the authorized generic version of Epclusa, Harvoni, the authorized generic version of Harvoni, Sovaldi and Vosevi. HBV includes Hepsera (adefovir dipivoxil), Vemlidy (tenofovir alafenamide), and Viread (tenofovir disoproxil fumarate). HDV includes Hepcludex (bulevirtide). Hepcludex (bulevirtide-gmod) was granted FDA accelerated approval for the treatment of chronic HDV in adults without cirrhosis or with compensated cirrhosis. Note: YoY reflects Q226 vs. Q225 and QoQ reflects Q226 vs. Q126. HBV – hepatitis B virus, HCV – hepatitis C virus, HDV – hepatitis delta virus, PBC – primary biliary cholangitis.

Trodelvy: Strength Across Breast Cancer Portfolio

Product Sales ($M)



TRODELVY®

+26%
YoY growth in Q226

#1
2L mTNBC[1] share

- **+26% YoY and +13% QoQ** primarily due to increased demand across metastatic breast cancer indications in all regions
- Approved in 1L mTNBC across PD-L1 status in U.S. in June 2026

Note: YoY reflects Q226 vs. Q225 and QoQ reflects Q226 vs. Q126. Trodelvy (sacituzumab govitecan-hziy) for injection. 1. U.S. and EU. Trodelvy is indicated for 1L mTNBC in adult patients with unresectable locally advanced or metastatic TNBC, as either a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy or in combination with pembrolizumab for patients whose tumors express PD-L1 (CPS ≥10). mTNBC – metastatic triple-negative breast cancer.

Cell Therapy: Preparing for Anito-Cel Launch

Product Sales ($M)



YESCARTA® (axicabtagene ciloleucel) Suspension for IV infusion

TECARTUS® (brexucabtagene autoleucel) Suspension for IV infusion

$417M
Q226 Cell Therapy Sales

>36K
Patients Treated to Date

>600
ATCs Globally

- -14% YoY reflecting continued competitive headwinds across regions; +2% QoQ driven by increased U.S. and Rest of World demand for Yescarta, partially offset by Tecartus
- Anito-cel PDUFA December 23, 2026, launch preparations well-underway

Yescarta (axicabtagene ciloleucel) suspension for IV infusion. Tecartus (brexucabtagene autoleucel) suspension for IV infusion. Note: YoY reflects Q226 vs. Q225 and QoQ reflects Q226 vs Q126. Anito-cel - anitocabtagene autoleucel. ATC- authorized treatment center.

Most Robust Launch Pipeline in Gilead's History



Note: This is illustrative and subject to timing of regulatory approvals, which may not reflect actual launch outcomes. Livdelzi was granted FDA accelerated approval in August 2024. Hepcludex (bulevirtide-gmod) was granted FDA accelerated approval for the treatment of chronic HDV in adults without cirrhosis or with compensated cirrhosis. Trodelvy is indicated for 1L mTNBC in adult patients with unresectable locally advanced or metastatic TNBC, as either a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy or in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for patients whose tumors express PD-L1 (CPS ≥10). BIC/LEN – bictegravir/lenacapavir, ISL/LEN – islatravir/lenacapavir, MM – multiple myeloma, mTNBC – metastatic triple negative breast cancer, PBC – primary biliary cholangitis, PrEP – pre-exposure prophylaxis, PWH – people with HIV, R/R – relapsed and/or refractory, VS – virally suppressed. Anito-cel - anitocabtagene autoleucel.

GILEAD
Creating Possible

Pipeline Updates

Dietmar Berger, MD, PhD
Chief Medical Officer

Lenacapavir Unlocks Broad HIV Pipeline



Note: All launch dates are subject to regulatory approval. Timeline estimates are as of August 2026 and subject to revision. Planned data readouts and regulatory submissions not necessarily in chronological order. For non-registrational studies, data readouts listed may be interim readouts. The use of lenacapavir as shown on this slide, alone or in combination with other antiretroviral candidates, is investigational; the safety and efficacy of these uses have not been established. Islatravir + lenacapavir is being developed in collaboration with our partner, Merck. FPI – first patient in, INSTI – integrase strand transfer inhibitor, PrEP – pre-exposure prophylaxis, TAB – teropavimab, ZAB – zinlirvimab

Liver Disease: Advancing Options for High Unmet Need

HEPCLUDEX

First-and-only FDA & EC approved treatment for chronic HDV infection

- EC conditional approval in July 2020 and full EU marketing authorization in July 2023
- FDA accelerated approval in May 2026

Livdelzi® seladelpar 10mg Capsules

Leading FDA & EC approved treatment for 2L PBC in inadequate responders to UDCA

- Accelerated Approvals supported by P3 RESPONSE trial in 2L PBC patients with ALP>1.67x ULN
- Announced positive P3 IDEAL results in 2L PBC patients with ALP 1-1.67x ULN – detailed data at future medical congress

ALP – alkaline phosphatase, EC – European Commission, HDV – hepatitis delta virus, PBC – primary biliary cholangitis, UDCA – ursodeoxycholic acid, ULN – upper limit of normal. Livdelzi received FDA accelerated approval in August 2024 and EC conditional approval in February 2025.

Oncology: Advancing Leading ADC Pipeline



GS-8824

(Previously TUB-040)



Note: GS-8824 also remains under evaluation for lung cancer

ADC – antibody drug conjugate, ASCO – American Society of Clinical Oncology, mBC – metastatic breast cancer, mTNBC – metastatic triple negative breast cancer, PROC – platinum resistant ovarian cancer, PSOC – platinum susceptible ovarian cancer.

Cell Therapy: Upcoming Launch & Long-Term Innovation

Upcoming Anito-Cel Launch

Large Unmet Need in Multiple Myeloma

- ~3.5B CAR T Addressable Market in 4L+ R/R MM

Best-in-Disease Potential

- Observed Deep & Durable Efficacy
- Differentiated Safety Profile
- Rapid and Reliable Manufacturing

4L R/R Multiple Myeloma FDA Decision Expected by 23 December 2026

Completed Enrollment of P3 iMMagine-3; Filing in 2-4L R/R MM as Early as 2027

In Vivo Platform in Development

Differentiated to Address Class Challenges

- Arcellx's small D-Domain binder bypasses payload challenges to target multiple antigens
- Plug-and-play modular Interius platform optimizes CARs / vector targets by diseases
- Pregene collaboration enables speed to clinic, initial investigator-sponsored studies exploring platform in 2H26

Designed for Scalability and Broad Expansion Across Oncology & Autoimmune Diseases

Note: anitocabtagene autoleucel (anito-cel) is an investigational therapy and is not approved for any indication. Launch of anito-cel is subject to regulatory approval. R/R MM – relapsed and/or refractory multiple myeloma. CARs – chimeric antigen receptors.

Key 2026 Milestones

✓ Completed ✓ Completed[1] ○ On Track

1H26

Program	Trial	Indication	Update	Status
ISL/LEN	ISLEND-1	QW Oral HIV Tx	Phase 3 Update	✓
	ISLEND-2	QW Oral HIV Tx	Phase 3 Update	✓
Hepcludex	MYR301	HDV	FDA Decision	✓

2H26

Program	Trial	Indication	Update	Status
BIC/LEN	ARTISTRY-1 & -2	QD Oral HIV Treatment	FDA Decision	○
Trodelvy	ASCENT-03	1L mTNBC (PD-L1-)	FDA Decision	✓
	ASCENT-04	1L mTNBC (PD-L1+)	FDA Decision	✓
	ASCENT-GYN	2L+ Advanced Endometrial Cancer	Phase 3 Update	○
	EVOKE-03	1L mNSCLC (PD-L1 High, TPS≥50%)	Phase 3 Update[1]	✓
Anito-cel	iMMagine-1	4L+ R/R Multiple Myeloma	FDA Decision	○
Livdelzi	IDEAL	2L Primary Biliary Cholangitis	Phase 3 Update	✓

1. Study did not meet primary endpoint and trial was discontinued. Data have been reviewed and will be shared at a scientific conference. Hepcludex (bulevirtide), Livdelzi (seladelpar), Trodelvy (sacituzumab govitecan-hziy). BIC - bictegravir, HDV - hepatitis delta virus, ISL - islatravir, LEN - lenacapavir, anito-cel (anitocabtagene autoleucel), mNSCLC - metastatic non-small cell lung cancer, mTNBC - metastatic triple-negative breast cancer, PD-L1 - programmed death-ligand 1, QD - daily, QW - weekly, R/R - relapsed or refractory, TPS - tumor proportion score.

GILEAD
Creating Possible

Financial Results

Andrew Dickinson
Chief Financial Officer

Q2 2026 Base Business Sales



Base Business Sales +10% YoY and +12% QoQ

- **YoY** primarily driven by HIV products, Trodelvy and Livdelzi partially offset by lower Cell Therapy and HCV products
- **QoQ** reflects growth across core therapeutic areas

Total Product Sales +8% YoY and +10% QoQ

- Reflecting lower Veklury sales due to fewer COVID-19 related hospitalizations

Note: YoY reflects Q226 vs. Q225 and QoQ reflects Q226 vs Q126.

Q2 2026 Non-GAAP Data

In millions, except percentages and per share amounts	Q225	Q226	YoY Change
COGS	$922	$999	8%
Product Gross Margin	87%	87%	Flat
R&D	$1,450	$1,429	-1%
Acquired IPR&D	$61	$11,183	NM
SG&A	$1,358	$1,521	12%
Non-GAAP Operating Expenses	**$2,869**	**$14,133**	**NM**
Non-GAAP Operating Income	**$3,290**	**$(7,329)**	**NM**
Operating Margin	46%	(94)%	NM
Effective Tax Rate	19%	(11)%	NM
Non-GAAP Net Income	**$2,521**	**$(8,391)**	**NM**
Non-GAAP Diluted EPS	$2.01	$(6.75)	NM
Shares used in per share calculation-diluted	**1,255**	**1,243**	

Non-GAAP Operating Expenses

- **R&D** relatively flat YoY, reflecting lower Oncology clinical study activity, offset by higher R&D costs associated with our newly acquired entities
- **Acquired IPR&D** primarily reflecting our investments in Arcellx, Tubulis, and Ouro Medicines, net of Lakefront collaboration
- **SG&A** up 12% YoY, primarily due to expected promotional activities related to Yeztugo

Non-GAAP EPS

- **Non-GAAP EPS** lower driven by higher acquired IPR&D, tax, and SG&A expenses, partially offset by higher revenue

Please refer to accompanying press release for disclosures about our use of non-GAAP financial measures and GAAP to non-GAAP reconciliations. Note: YoY reflects Q226 vs. Q225. NM – not meaningful.

Q2 2026 Illustrative Non-GAAP EPS



Q226 Illustrative Non-GAAP EPS +13% YoY

- Excluding $9.02 per share impact from Q2 acquisitions as well as non-recurring other revenues, illustrative non-GAAP EPS was $2.27
- Illustrative Non-GAAP EPS YoY primarily driven by higher product sales, partially offset by higher SG&A and tax expenses

Note: Illustrative non-GAAP EPS excludes acquired IPR&D expenses and financing costs related to acquisitions of Arcellx, Tubulis, and Ouro Medicines (net of Lakefront collaboration) in Q226, as well as other non-recurring, non-cash other revenues.

FY2026 Updated Guidance

	10 February 2026	7 May 2026	4 August 2026
Total Product Sales	$29.6B - $30.0B	$30.0B - $30.4B	$30.1B - $30.4B
Product Sales ex-Veklury	$29.0B - $29.4B	$29.4B - $29.8B	$29.8B - $30.1B
Veklury Sales	~ $600M	No Change	~ $300M
Non-GAAP			
Product Gross Margin	~ 87.0%	No Change	No Change
R&D Expense	Low-single digit % growth	Mid-single digit % growth	No Change
Acquired IPR&D	~ $0.3B	~ $11.8B	~ $11.5B
SG&A Expense	Mid-single digit % growth	No Change	No Change
Operating Income	$13.8B - $14.3B	$2.4B - $2.9B	$2.9B - $3.3B
Effective Tax Rate	~ 20%	190% - 140%	140% - 115%
Diluted EPS	$8.45 - $8.85	$(1.05) - $(0.65)	$(0.65) - $(0.30)
GAAP Diluted EPS	$6.75 - $7.15	$(3.25) - $(2.85)	$(3.75) - $(3.40)

Base Business Guidance +6% to +7% YoY

- Raised Base Business sales guidance by $350M at midpoint compared to May guidance, and by $750M at midpoint compared to February guidance
- Expect HIV to grow 9-10% YoY, including FY26 Yeztugo sales of ~$1B
- Cell Therapy expected to decline mid-teens % YoY

Non-GAAP Operating Expenses

- No change to R&D and SG&A expense guidance
- Lowered acquired IPR&D by ~$300M due to revision of the accounting treatment of potential future milestones associated with Tubulis acquisition
- Raised Non-GAAP diluted EPS guidance by ~$0.38 at midpoint driven by lower acquired IPR&D and higher revenues

This financial guidance excludes the impact of any expenses related to potential acquisitions or business development transactions that have not been executed, future fair value adjustments of equity securities and discrete tax charges or benefits associated with changes in tax related laws and guidelines as Gilead is unable to project such amounts. This guidance is subject to a number of risks and uncertainties. See Forward-Looking Statements on page 2. Please refer to the accompanying press release for GAAP to non-GAAP reconciliations.

FY2026 Illustrative Non-GAAP EPS Guidance



Illustrative August EPS Guidance

- Raised $0.05 on the bottom end due to higher base business sales, partially offset by lower Veklury compared to Illustrative May guidance

Note : Illustrative non-GAAP EPS excludes acquired IPR&D expenses and financing costs related to acquisitions of Arcellx, Tubulis, andOuro Medicines (net of Lakefront collaboration), as well as other non-recurring, non-cash other revenues.

Ongoing Commitment to Disciplined Capital Deployment

~$1B

Dividends Paid in Q226

$355M

In Shares Repurchased in Q226[1]

2.7M Shares at Average $131.83

Capital Allocation Priorities

- Continue to invest in our business and R&D pipeline while managing expenses
- Continue ordinary course partnerships and business development transactions
- Grow our dividend
- Repurchase shares to offset dilution and opportunistically reduce share count

1. Repurchases of common stock under repurchase program.

Q&A

Daniel O'Day
Chairman &
Chief Executive Officer

Johanna Mercier
Chief Commercial &
Corporate Affairs Officer

Dietmar Berger, MD, PhD
Chief Medical Officer

Andrew Dickinson
Chief Financial Officer

Cindy Perettie
EVP & Head of Kite

Robust Pipeline with Upcoming Catalysts

53 Clinical programs[1] **4** Clinical opt-in assets



Pipeline shown above as of Q2 2026. 1. Program count does not include potential partner opt-in programs or programs that have received both FDA and EC approval. Anito-cel - anitocabtagene autoleucel, Axi-cel - axicabtagene ciloleucel, BIC - bictegravir, FL - follicular lymphoma, HDV – hepatitis delta virus, HIV - human immunodeficiency virus, HR – high risk, ISL - islatravir, LAI – long acting injectable, LAO – long acting oral, LBCL - large B-cell lymphoma, LEN - lenacapavir, mEC – metastatic endometrial cancer, MM – multiple myeloma, mTNBC – metastatic triple-negative breast cancer, PD-L1 – programmed death ligand 1, pembro – pembrolizumab, PrEP - pre-exposure prophylaxis, R/R – relapsed or refractory, SCLC – small cell lung cancer, SG - sacituzumab govitecan-hziy, TNBC – triple-negative breast cancer

Viral Diseases Pipeline 1/2

Clinical Program	Indication	Phase 1	Phase 2	Phase 3	Filed	Q2'26 Updates
HIV Prevention						
Yeztugo® (lenacapavir)	HIV PrEP LAO	★			sNDA submitted	sNDA Submitted
Lenacapavir (PURPOSE 365)	HIV PrEP LAI					
HIV Treatment						
Bictegravir/lenacapavir oral combination (ARTISTRY-1 & -2)	HIV Oral				NDA submitted	
Islatravir/lenacapavir oral combination (ISLEND-1 &-2)[1]	HIV LAO					
HIV INSTI/capsid inhibitor (GS-1720/GS-4182) (WONDERS-1)[2]	HIV LAO	▲	Clinical hold			Clinical hold lifted GS-1720
HIV capsid inhibitor (GS-3107)	HIV LAO					
HIV INSTI (GS-3242) + lenacapavir	HIV LAO	★				P2 Planned 2H26
Lenacapavir + teropavimab + zinlirvimab	HIV LAI	●				
HIV INSTI (GS-3242) + lenacapavir	HIV LAI	★				P2 FPI
HIV INSTI (GS-1219)[3]	HIV LAI					
HIV Cure						
Teropavimab + zinlirvimab[4]	HIV Cure					
Vesatolimod	HIV Cure					
HIV bispecific T-cell engager (GS-8588)	HIV Cure					

Pipeline shown above as of Q2 2026. 1. Subject to Gilead and Merck co-development and co-commercialization agreement. 2. Program timelines pending resolution of the GS-4182 clinical hold. 3. Development paused. 4. Non-Gilead sponsored trial(s) ongoing. FPI – first patient in, HIV - human immunodeficiency virus, INSTI - integrase strand transfer inhibitor, LAI – long-acting injectable, LAO – long-acting oral, sNDA – supplemental new drug application, PrEP - pre-exposure prophylaxis.

Viral Diseases Pipeline 2/2

Clinical Program	Indication	Phase 1	Phase 2	Phase 3	Filed	Q2'26 Updates
HDV						
Hepcludex® (MYR301)	HDV	▲ P ●		BLA and MAA Approved		FDA approval granted
HDV pre-S1 nAb (GS-4321)	HDV					
HBV Cure						
HBV therapeutic vaccine (GS-2829 + GS-6779)	HBV Cure					
HSV						
HSV HPI (GS-1179)	HSV					
Infectious Disease						
CoV Mpro Inhibitor (GS-1701)	NEVPP					
Opt-ins						
Assembly Biosciences	HDV	1 clinical stage program				

Pipeline shown above as of Q2 2026. BLA – biologics license application, CoV – covid, FDA – food and drug administration, HBV – hepatitis B virus, HDV – hepatitis delta virus, HPI - helicase-primase inhibitor, HSV – herpes simplex virus, MAA - marketing authorization application, NEVPP – neglected and emerging viruses and pandemic preparation.

Cell Therapy Pipeline

★ New listing in Q2'26
● Breakthrough Therapy Designation
▲ Q2'26 Updates
P PRIME Designation
R RMAT Designation

Clinical Program	Indication	Phase 1	Phase 2	Phase 3	Filed	Q2'26 Updates
Lymphoma						
Axicabtagene ciloleucel (ZUMA-22)	2L+ HR FL					
Axicabtagene ciloleucel (ZUMA-23)	1L HR LBCL					
CD19/CD20 bicistronic (KITE-753) (PALISADES-2)[1]	2L DLBCL	★ R				P3 FPI
CD19/CD20 bicistronic (KITE-753) (PALISADES-1)[1]	3L+ R/R DLBCL	R				
Brexucabtagene autoleucel (ZUMA-4)	Pediatric ALL/NHL					
Multiple Myeloma						
Anitocabtagene autoleucel (iMMagine-1)	4L+ R/R MM				BLA Filed	
Anitocabtagene autoleucel (iMMagine-3)	2-4L R/R MM					
Autoimmune Diseases						
CD19/CD20 bicistronic (KITE-363)	Rheumatology					
CD19/CD20 bicistronic (KITE-363)	Neurology					
Anitocabtagene autoleucel	gMG					

Pipeline shown above as of Q2 2026. 1. Manufacturing innovation. ALL - acute lymphocytic leukemia, BLA - biological license application, DLBCL - diffuse large B-cell lymphoma, FL - follicular lymphoma, FPI - first patient in, gMG - generalized myasthenia gravis, HR - high risk, LBCL - large B cell lymphoma, MM - multiple myeloma, NHL - non-Hodgkin's lymphoma, R/R - relapsed or refractory, RMAT - regenerative medicine advanced therapy.

Oncology Pipeline 1/2

★ New listing in Q2'26 ▲ Q2'26 Updates
● Breakthrough Therapy Designation P PRIME Designation

Clinical Program	Indication	Phase 1	Phase 2	Phase 3	Filed	Q2'26 Updates
Breast						
Sacituzumab govitecan-hziy (ASCENT-03)	1L mTNBC (PD-L1-)	▲			sBLA and MAA approved	FDA approval granted
Sacituzumab govitecan-hziy + pembrolizumab (ASCENT-04)[1]	1L mTNBC (PD-L1+)	▲			sBLA approved and MAA submitted	FDA approval granted
Sacituzumab govitecan-hziy + pembrolizumab (ASCENT-05)	High risk adjuvant TNBC					
Lung & Thoracic						
Sacituzumab govitecan-hziy (EVOKE-SCLC-04)	2L ES-SCLC	●				
Gastric Intestinal						
Denikitug	mCRC	★				P2 FPI
Gynecology						
Sacituzumab govitecan-hziy (ASCENT-GYN-01)[2]	2L+ mEC					
NaPi2b ADC (GS-8824) (NAPISTAR 1-01)[3]	2L+ PROC	★				Acquired from Tubulis
NaPi2b ADC (GS-8824) (NAPISTAR 1-02)[3]	2L+ PSOC	★				Acquired from Tubulis

Pipeline shown above as of Q2 2026. Removed programs: Phase 3 Sacituzumab govitecan-hziy + pembrolizumab (EVOKE-03) for 1L mNSCLC (PDL1+, TPS ≥ 50%). Phase 2 Lung Cancer Platform (VELOCITY-Lung) for NSCLC. Phase 2 Sacituzumab govitecan-hziy + combinations (TROPHY U-01) in mUC. 1. In collaboration with Merck. 2. In collaboration with the GOG Foundation (GOG) and European Network of Gynecological Oncological Trial Groups (ENGOT). 3. Previously TUB-40. ES-SCLC - extensive stage - small cell lung cancer, FDA – food and drug administration, FPI – first patient in, MAA - marketing authorization application, mCRC – metastatic colorectal cancer, mEC – metastatic endometrial cancer, mTNBC – metastatic triple-negative breast cancer, mUC - metastatic urothelial carcinoma, PD-L1 – programmed death-ligand 1, PROC – platinum-resistant ovarian cancer, PSOC – platinum-sensitive ovarian cancer, sBLA – supplemental biologics license application, TNBC – triple-negative breast cancer.

Oncology Pipeline 2/2

★ New listing in Q2'26 ▲ Q2'26 Updates
● Breakthrough Therapy Designation P PRIME Designation

Clinical Program	Indication	Phase 1	Phase 2	Phase 3	Filed	Q2'26 Updates
Advanced Cancers						
Efarindodekin Alfa[1]	Advanced Cancers	▲				P1 → P2
5T4 ADC (GS-8823)[2]	Advanced Cancers	★				Acquired from Tubulis
Anti -IL-18BP (GS-0321)[3]	Advanced Cancers					
Denikitug	Advanced Cancers					
GS-2121	Advanced Cancers					
GS-2426	Advanced Cancers	★				P1 FPI
GS-5319	Advanced Cancers					
PARP1 inhibitor (GS-0201)	Advanced Cancers					
Opt-ins						
Arcus	Advanced Cancers	2 clinical stage program				
MacroGenics	Advanced Cancers	1 clinical stage program				

Pipeline shown above as of Q2 2026. 1. Operationalized by Xilio, previously XTX301. 2. Previously TUB-30. 3. Operationalized by Compugen. PARP1 – poly (ADP-ribose) polymerase 1.

Inflammatory Diseases Pipeline

★ New listing in Q2'26 ▲ Q2'26 Updates
● Breakthrough Therapy Designation P PRIME Designation

Clinical Program	Indication	Phase 1	Phase 2	Phase 3	Filed	Q2'26 Updates
Lupus						
Edecesertib (COSMIC)	Lupus					
Inflammatory Bowel Disease						
Tilpisertib fosmecarbil (PALEKONA)	IBD					
Emvistegrast (SWIFT)[1]	IBD					
FXR agonist (GS-8670)	IBD					
Inflammatory Diseases						
Gamgertamig[2]	Inflammatory Diseases	★				Acquired from Ouro Medicines
CD200R agonist (GS-5305)	Inflammatory Diseases					
IRAK4 Degrader (GS-6791)	Inflammatory Diseases					
PD1 agonist (GS-0151)	Inflammatory Diseases					
Metabolic Disease						
GLP-1R agonist (GS-4571)	Metabolic Disease					

Pipeline shown above as of Q2 2026. 1. Previously GS-1427. 2. Gamgertamig is being investigated in autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and other inflammatory diseases. GLP-1 – glucagon-like peptide-1, IBD – inflammatory bowel disease, PD1 - programmed cell death protein 1.

GAAP to Non-GAAP Reconciliation of Outstanding Adjusted Debt and Adjusted EBITDA

in billions where applicable	As of				
	June 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
Total Debt, net	$24.95	$24.94	$24.94	$22.17	$26.25
Debt Discounts, Premiums and Issuance Costs	0.18	0.18	0.17	0.17	0.18
Liability related to sale of future royalties[1]	(1.13)	(1.12)	(1.11)	(1.09)	(1.08)
Total Adjusted Debt[1]	**$24.00**	**$24.00**	**$24.00**	**$21.25**	**$25.35**

	Twelve Months Ended				
	June 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
Net Income attributable to Gilead	$6.31	$8.11	$8.51	$9.22	(3.24)
Add: Interest Expense[2] & Other (Income) expense, net	0.85	0.60	0.23	(0.36)	(0.54)
Add: Tax	0.89	1.78	1.29	1.51	1.28
Add: Depreciation	0.38	0.38	0.37	0.38	0.37
Add: Amortization	2.39	2.39	2.39	2.39	2.39
Add: Initial costs of externally developed IPR&D projects[3]	0.32	0.43	0.81	0.64	11.72
Add: Impairments	1.94	0.19	0.59	0.59	2.15
Adjusted EBITDA[4]	**$13.08**	**$13.88**	**$14.18**	**$14.37**	**$14.14**
Adjusted Debt to Adjusted EBITDA ratio[4]	**~1.83x**	**~1.73x**	**~1.69x**	**~1.48x**	**~1.79x**

1. Adjusted debt excludes a funding agreement with RPI Finance Trust that was assumed as part of our acquisition of Immunomedics under which Immunomedics received cash in exchange for perpetual, tiered royalty payments on worldwide sales of Trodelvy.
2. Total interest expense and amortization from all issued debt is expected to be $1 billion for the full year 2026. We retain the flexibility to refinance or to repay maturing debt.
3. Represents the initial costs of externally developed IPR&D projects with no alternative future use, acquired directly in a transaction other than a business combination, including upfront payments related to various collaborations and the initial costs of rights to IPR&D projects.
4. Adjusted EBITDA and Adjusted Debt to Adjusted EBITDA ratio are non-GAAP performance measures used by our investors and analysts to assess the overall operating performance in the context of financial leverage.